Preferred therapies for severe COVID-19/ Cytokine Release Syndrome
% of Respondents (N=14)
Available Clinical Trials
% of Respondents (N=14)
Anti-virals (Remdesivir, Lopinavir/Ritonavir, Ribavirin, Arbidol, Favipiravir) 46.2% Remdesivir 72.7%
Hydroxychloroquine or chloroquine 30.8% Lopinvir/ritonavir 36.4%
Anti- IL6 (Tocilizumab) 15.4% Hydroxychloroquine or chloroquine 45.5%
Corticosteroids 7.7% Convalescent plasma 36.4%
Intravenous immunoglobulins (IVIg) 7.7% Anti-IL6 (Tocilizumab) 27.3%
Corticosteroids 27.3%
Favipiravir 18.2%
Interferons 9.1%
Ribavarin 9.1%